eligibility_summary
Eligible: adults (≥18) able to consent, negative serum pregnancy test and effective contraception if applicable. Exclude: receipt of T-cell depleting antibodies within 28 days (ATG, OKT3, Campath), pregnancy, any condition or lab abnormality that could affect outcomes, active uncontrolled GVHD (acute grade II–IV or progressive extensive chronic) at enrollment or infusion.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: Donor-derived EBV-specific T cells (biologic, adoptive cellular immunotherapy). These are ex vivo–expanded, polyclonal CD8+/CD4+ T cells generated from the allogeneic stem cell donor’s G-CSF–mobilized graft and infused 1–4 times post-transplant as consolidation. Mechanism of action: HLA-restricted T-cell receptor recognition of EBV antigens (e.g., EBNA, LMP) presented on malignant or infected cells, leading to cytotoxic clearance via perforin/granzyme and Th1 cytokines, restoration of antiviral immunity, reduction of EBV viremia, and control of EBV-driven lymphoproliferation/HLH. Targets: EBV-infected/malignant T/NK (and potentially B) cells, pathways include adaptive cellular immunity and graft-versus-lymphoma effects with minimized GVHD risk.